Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Rangering i aksjer #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Aksjekurs
$9.60
Sist synkronisert: 2025-05-21
Markedsverdi
$1.08B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel OptiNose, Inc. (OPTN)

Kategori

P/E-forhold for OptiNose, Inc. (OPTN)
P/E-forhold per August 2026 TTM: -4.53
Ifølge OptiNose, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) -4.53. Ved slutten av 2023 hadde selskapet en P/E på -61.12.
P/E-forholdshistorikk for OptiNose, Inc. fra 2015 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
2026 (TTM) -4.53 43.76%
2024 -3.15 -94.85%
2023 -61.12 2,778.17%
2022 -2.12 -87.45%
2021 -16.92 -44.50%
2020 -30.49 -42.65%
2019 -53.16 53.32%
2018 -34.67 -82.13%
2017 -194.05 -666.28%
2016 34.27 -112.74%
2015 -268.92 0.00%
P/E-forhold for lignende selskaper eller konkurrenter
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.